Ask AI
Pemigatinib in mCRC
Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations

Released: January 30, 2023

Activity

Progress
1
Course Completed